title: Oral glucocorticoid treatment decreases interleukin-10 receptor expression on peripheral blood leucocyte subsets.
abstract: Glucocorticoids (GCS) are capable of stimulating the secretion of interleukin (IL)-10 by leucocytes; however, the potential of GCS to modulate leucocyte susceptibility to IL-10-mediated actions has not yet been studied. In the current paper, we performed a detailed cross-sectional analysis of IL-10 receptor (IL-10R) expression by CD4(+) and CD8(+) T cells, natural killer (NK) cells, monocytes and neutrophils. Next, we analysed the effects of short-term oral GCS treatment on surface IL-10R expression by various leucocyte subpopulations in asthmatic patients. All leucocyte subsets studied presented with substantial levels of surface IL-10R. The highest levels of IL-10R were found on monocytes, predominantly with CD14(2+)CD16(+) and CD14(+)CD16(+) phenotypes, and on CD4(+)CD25(high) T cells. In contrast, levels of IL-10R on CD8(+) T cells, NK cells and neutrophils were significantly lower and similar to each other in intensity. GCS treatment resulted in a significant decrease of IL-10R expression on all analysed peripheral blood leucocyte subsets. Our data suggest that down-regulation of IL-10R could counterbalance the otherwise suppressive action of GCS.
authors.affiliation: Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland. moniuszm@umwb.edu.pl
authors.forename: M
authors.initials: M
authors.lastname: Moniuszko
authors.forename: A
authors.initials: A
authors.lastname: Bodzenta-Lukaszyk
authors.forename: M
authors.initials: M
authors.lastname: Dabrowska
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D016022:Case-Control Studies; D015536:Down-Regulation; D005434:Flow Cytometry / Q000379:methods; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D007694:Killer Cells, Natural / Q000187:drug effects / Q000378:metabolism; D007962:Leukocytes / Q000187:drug effects / Q000378:metabolism*; D008775:Methylprednisolone / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D053701:Receptors, Interleukin-10 / Q000032:analysis / Q000378:metabolism*; D018709:Statistics, Nonparametric
chemical_list: D005938:Glucocorticoids; D053701:Receptors, Interleukin-10; D008775:Methylprednisolone